scispace - formally typeset
M

Mark Rosenbach

Researcher at Merck & Co.

Publications -  31
Citations -  3883

Mark Rosenbach is an academic researcher from Merck & Co.. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 21, co-authored 31 publications receiving 3694 citations. Previous affiliations of Mark Rosenbach include United States Military Academy.

Papers
More filters
Journal ArticleDOI

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

TL;DR: It is shown that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolites of the immunosuppressive agent FTY720.
Journal ArticleDOI

Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720

TL;DR: The results with these Sphk1 null mice reveal that some key physiologic processes that require S1P receptor signaling, such as vascular development and proper lymphocyte distribution, can occur in the absence of SPHK1.
Journal ArticleDOI

Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes

TL;DR: Three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compound potency on S 1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus brady Cardia and hypertension was consistent with affinity for S1 p1 relative to S1p3; and toxicity, brady cardia, and hypertension were absent in S1 P3-/- mice.
Journal ArticleDOI

Discovery of Novel Antifungal (1,3)-β-d-Glucan Synthase Inhibitors

TL;DR: Results of natural-product screening by a series of newly developed methods has led to the identification of four acidic terpenoid (1,3)-β-d-glucan synthase inhibitors, which have limited oral bioavailability and in vitro antifungal activity comparable to that of L-733560, a close analogue of MK-0991.
Journal ArticleDOI

Khafrefungin, a Novel Inhibitor of Sphingolipid Synthesis

TL;DR: Khafrefungin, which is composed of aldonic acid linked via an ester to a C22 modified alkyl chain, has fungicidal activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae.